{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T22:59:26Z","timestamp":1782860366924,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,5]]},"DOI":"10.7759\/cureus.89432","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T16:48:14Z","timestamp":1754412494000},"source":"Crossref","is-referenced-by-count":1,"title":["Hospital Admissions and Antimicrobial Resistance Patterns in Diabetic Patients With Urinary Tract Infections: A Cross-Sectional Study From a Tertiary Care Center in Pakistan"],"prefix":"10.7759","author":[{"given":"Ali","family":"Raza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Numan","family":"Pervaiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irfan","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam bint","family":"Shafqat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Zubair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misbah Shirin","family":"Memon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiza Sobia","family":"Ramzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21720","article-title":"Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin","volume":"14","author":"Khan S","year":"2022","unstructured":"Khan S, Hashmi MS, Rana MA, Zafar GM, Asif S, Farooq MT, Zahoor S. Frequency of urinary tract infections in type 2 diabetic patients taking dapagliflozin. Cureus. 2022, 14:e21720. 10.7759\/cureus.21720","journal-title":"Cureus"},{"key":"ref2","article-title":"IDF Diabetes Atlas [Internet] 10th Edition","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ, IDF Diabetes Atlas 10th edition scientific committee. IDF Diabetes Atlas [Internet] 10th Edition. International Diabetes Federation, Brussels; 2021."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2022.103901","article-title":"The increasing rate of diabetes in Pakistan: a silent killer","volume":"3","author":"Azeem S","year":"2022","unstructured":"Azeem S, Khan U, Liaquat A. The increasing rate of diabetes in Pakistan: a silent killer. Ann Med Surg. 2022, 3:103901. 10.1016\/j.amsu.2022.103901","journal-title":"Ann Med Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2165\/11209910-000000000-00000","article-title":"Dapagliflozin: a review of its use in type 2 diabetes mellitus","volume":"72","author":"Plosker GL","year":"2012","unstructured":"Plosker GL. Dapagliflozin: a review of its use in type 2 diabetes mellitus. Drugs. 2012, 72:2289-312. 10.2165\/11209910-000000000-00000","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0606","article-title":"Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial","volume":"34","author":"Nauck MA","year":"2011","unstructured":"Nauck MA, Del Prato S, Meier JJ, Dur\u00e1n-Garc\u00eda S, Rohwedder K, Elze M, Parikh SJ. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011, 34:2015-22. 10.2337\/dc11-0606","journal-title":"Diabetes Care"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7753(13)70062-9","article-title":"Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2 [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]","volume":"2","author":"Albarr\u00e1n OG","year":"2013141","unstructured":"Albarr\u00e1n OG, Ampudia-Blasco FJ. Dapagliflozina, el primer inhibidor SGLT 2 en el tratamiento de la diabetes tipo 2 [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]. Med Clin. 2013141, 2:36-43. 10.1016\/S0025-7753(13)70062-9","journal-title":"Med Clin"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2011-2260","article-title":"Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin","volume":"97","author":"Bolinder J","year":"2012","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, et al.. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012, 97:1020-31. 10.1210\/jc.2011-2260","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-022-00644-9","article-title":"The prevalence of urinary tract infections in type 2 diabetic patients: a systematic review and meta-analysis","volume":"27","author":"Salari N","year":"2022","unstructured":"Salari N, Karami MM, Bokaee S, Chaleshgar M, Shohaimi S, Akbari H, Mohammadi M. The prevalence of urinary tract infections in type 2 diabetic patients: a systematic review and meta-analysis. Eur J Med Res. 2022, 27:20. 10.1186\/s40001-022-00644-9","journal-title":"Eur J Med Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.31842","article-title":"Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and genital infections in patients with diabetic mellitus and concomitant coronary artery disease: a single-center experience","volume":"14","author":"Shah BR","year":"2022","unstructured":"Shah BR, Phatak S, Phatak P, Shah HB, Phatak I, Shah DB. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and genital infections in patients with diabetic mellitus and concomitant coronary artery disease: a single-center experience. Cureus. 2022, 14:e31842. 10.7759\/cureus.31842","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-014-0072-0","article-title":"Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48\u00a0weeks: a randomized, double-blind, parallel-group, placebo-controlled trial","volume":"5","author":"Strojek K","year":"2014","unstructured":"Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48\u00a0weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther. 2014, 5:267-83. 10.1007\/s13300-014-0072-0","journal-title":"Diabetes Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4066\/AMJ.2014.2181","article-title":"SGLT2 inhibitors: new medicines for addressing unmet needs in type 2 diabetes","volume":"7","author":"Moses RG","year":"2014","unstructured":"Moses RG, Colagiuri S, Pollock C. SGLT2 inhibitors: new medicines for addressing unmet needs in type 2 diabetes. Australas Med J. 2014, 7:405-15. 10.4066\/AMJ.2014.2181","journal-title":"Australas Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212264","article-title":"Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents","volume":"3","author":"Vivian EM","year":"2014","unstructured":"Vivian EM. Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents. Drugs Context. 2014, 3:212264. 10.7573\/dic.212264","journal-title":"Drugs Context"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/medicina60111870","article-title":"Characteristics of urinary tract infections in patients with diabetes from Timi\u0219oara, Romania: prevalence, etiology, and antimicrobial resistance of uropathogens","volume":"60","author":"Sorescu T","year":"2024","unstructured":"Sorescu T, Licker M, Timar R, et al.. Characteristics of urinary tract infections in patients with diabetes from Timi\u0219oara, Romania: prevalence, etiology, and antimicrobial resistance of uropathogens. Medicina (Kaunas). 2024, 60:10.3390\/medicina60111870","journal-title":"Medicina (Kaunas)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-090419-102644","article-title":"Prediabetes and what it means: the epidemiological evidence","volume":"42","author":"Echouffo-Tcheugui JB","year":"2021","unstructured":"Echouffo-Tcheugui JB, Selvin E. Prediabetes and what it means: the epidemiological evidence. Annu Rev Public Health. 2021, 42:59-77. 10.1146\/annurev-publhealth-090419-102644","journal-title":"Annu Rev Public Health"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20080020","article-title":"Epidemiology of diabetes and diabetes-related complications","volume":"88","author":"Deshpande AD","year":"2008","unstructured":"Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008, 88:1254-64. 10.2522\/ptj.20080020","journal-title":"Phys Ther"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(17)30058-2","article-title":"Type 2 diabetes","volume":"389","author":"Chatterjee S","year":"2017","unstructured":"Chatterjee S, Khunti K, Davies MJ. Type 2 diabetes. Lancet. 2017, 389:2239-51.","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S447835","article-title":"Assessment of the negative factors for the clinical outcome in patients with SARS-CoV-2 infection and type 2 diabetes mellitus","volume":"17","author":"Albai O","year":"2024","unstructured":"Albai O, Braha A, Timar B, Sima A, Deaconu L, Timar R. Assessment of the negative factors for the clinical outcome in patients with SARS-CoV-2 infection and type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2024, 17:271-82. 10.2147\/DMSO.S447835","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58020271","article-title":"Association of Proteus mirabilis and Providencia stuartii infections with diabetes","volume":"58","author":"Rus M","year":"2022","unstructured":"Rus M, Licker M, Musuroi C, et al.. Association of Proteus mirabilis and Providencia stuartii infections with diabetes. Medicina (Kaunas). 2022, 58:10.3390\/medicina58020271","journal-title":"Medicina (Kaunas)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S51792","article-title":"Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management","volume":"8","author":"Nitzan O","year":"2015","unstructured":"Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015, 8:129-36. 10.2147\/DMSO.S51792","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59101747","article-title":"Particularities of urinary tract infections in diabetic patients: a concise review","volume":"59","author":"Confederat LG","year":"2023","unstructured":"Confederat LG, Condurache MI, Alexa RE, Dragostin OM. Particularities of urinary tract infections in diabetic patients: a concise review. Medicina (Kaunas). 2023, 59:10.3390\/medicina59101747","journal-title":"Medicina (Kaunas)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/395114-hospital-admissions-and-antimicrobial-resistance-patterns-in-diabetic-patients-with-urinary-tract-infections-a-cross-sectional-study-from-a-tertiary-care-center-in-pakistan","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T16:48:15Z","timestamp":1754412495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/395114-hospital-admissions-and-antimicrobial-resistance-patterns-in-diabetic-patients-with-urinary-tract-infections-a-cross-sectional-study-from-a-tertiary-care-center-in-pakistan"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.89432","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,5]]}}}